How does ImmunoGen Inc. (IMGN) change from a tortoise to a hare?

ImmunoGen Inc. (NASDAQ: IMGN) stock jumped 4.90% on Friday to $4.92 against a previous-day closing price of $4.69. With 2.61 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.79 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.2000 whereas the lowest price it dropped to was $4.7900. The 52-week range on IMGN shows that it touched its highest point at $7.77 and its lowest point at $3.10 during that stretch. It currently has a 1-year price target of $11.85. Beta for the stock currently stands at 1.03.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMGN was down-trending over the past week, with a drop of -7.69%, but this was up by 0.41% over a month. Three-month performance dropped to -2.57% while six-month performance fell -14.73%. The stock lost -12.92% in the past year, while it has lost -33.69% so far this year. A look at the trailing 12-month EPS for IMGN yields -0.60 with Next year EPS estimates of -0.75. For the next quarter, that number is -0.25. This implies an EPS growth rate of -168.30% for this year and 11.00% for next year.

Float and Shares Shorts:

At present, 253.26 million IMGN shares are outstanding with a float of 219.65 million shares on hand for trading. On Jul 14, 2022, short shares totaled 14.86 million, which was 6.74% higher than short shares on Jun 14, 2022. In addition to Mr. Mark Joseph Enyedy as the firm’s Pres, CEO & Director, Ms. Susan Altschuller Ph.D. serves as its Sr. VP & CFO.

Institutional Ownership:

Through their ownership of 94.66% of IMGN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 60.16% of IMGN, in contrast to 33.46% held by mutual funds. Shares owned by individuals account for 1.48%. As the largest shareholder in IMGN with 9.86% of the stake, RA Capital Management LP holds 21,741,458 shares worth 21,741,458. A second-largest stockholder of IMGN, The Vanguard Group, Inc., holds 15,048,665 shares, controlling over 6.82% of the firm’s shares. Deerfield Management Company LP is the third largest shareholder in IMGN, holding 14,779,590 shares or 6.70% stake. With a 6.41% stake in IMGN, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 14,144,457 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.93% of IMGN stock, is the second-largest Mutual Fund holder. It holds 6,455,819 shares valued at 29.05 million. iShares Russell 2000 ETF holds 2.24% of the stake in IMGN, owning 4,949,119 shares worth 22.27 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IMGN since 10 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With IMGN analysts setting a high price target of $20.00 and a low target of $4.00, the average target price over the next 12 months is $11.38. Based on these targets, IMGN could surge 306.5% to reach the target high and fall by -18.7% to reach the target low. Reaching the average price target will result in a growth of 131.3% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. IMGN will report FY 2022 earnings on 02/10/2023. Analysts have provided yearly estimates in a range of -$0.80 being high and -$1.03 being low. For IMGN, this leads to a yearly average estimate of -$0.87. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. ImmunoGen Inc. surprised analysts by -$0.03 when it reported -$0.24 EPS against a consensus estimate of -$0.21. The surprise factor in the prior quarter was $0.11. Based on analyst estimates, the high estimate for the next quarter is -$0.23 and the low estimate is -$0.29. The average estimate for the next quarter is thus -$0.26.

Summary of Insider Activity:

Insiders traded IMGN stock several times over the past three months with 5 Buys and 0 Sells. In these transactions, 14,911 shares were bought while 0 shares were sold. The number of buy transactions has increased to 13 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 105,176 while 0 shares were sold.

Leave a Comment

Your email address will not be published.